ProPhase Labs (NASDAQ:PRPH – Get Free Report) will be announcing its earnings results before the market opens on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.28) per share for the quarter. Persons that are interested in participating in the company’s earnings conference call can do so using this link.
ProPhase Labs (NASDAQ:PRPH – Get Free Report) last issued its quarterly earnings results on Thursday, March 28th. The company reported ($0.51) earnings per share for the quarter. The company had revenue of $3.50 million during the quarter, compared to analyst estimates of $10.71 million. ProPhase Labs had a negative net margin of 37.81% and a negative return on equity of 29.83%. On average, analysts expect ProPhase Labs to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
ProPhase Labs Stock Down 5.2 %
NASDAQ PRPH opened at $5.06 on Wednesday. The stock has a market capitalization of $91.33 million, a P/E ratio of -5.16 and a beta of -0.17. ProPhase Labs has a 52 week low of $4.05 and a 52 week high of $9.94. The company has a debt-to-equity ratio of 0.29, a quick ratio of 2.10 and a current ratio of 2.28. The stock has a fifty day moving average of $5.54 and a 200-day moving average of $5.04.
Analyst Ratings Changes
Get Our Latest Research Report on PRPH
About ProPhase Labs
ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.
Further Reading
- Five stocks we like better than ProPhase Labs
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Garmin Navigates to New Highs Driven By Wearables Trend
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Pinterest Prospers From AI Boosting Shop-Ability and Relevance
- When to Sell a Stock for Profit or Loss
- AbbVie Tracking for New Highs in 2024
Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.